anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: We describe long-term outcomes, including UTIs and need for reimplantation, after ureterovesicostomy (UV) as a lasting surgical procedure for children with primary obstructive megaureter (POM).
MATERIALS AND METHODS: Children referred to our institution between 2016 and 2023 who underwent refluxing UV were analyzed. POM was defined as hydroureteronephrosis with distal ureteral dilatation > 7 mm and a negative workup for other etiologies of hydronephrosis. We assessed for surgical outcomes, complications, rate of UTI, and improvement in upper tract dilatation. Statistical analyses assessed for change in hydronephrosis metrics over follow-up.
RESULTS: Among 183 patients diagnosed with POM, 47 (24%) underwent UV. Median age of presentation, surgery, and follow-up was 2, 9, and 43 months, respectively. A total of 7 patients developed 30-day complications: Clavien-Dindo grade 1 in 2 (transient urinary retention) and grade 2 in 5 (UTIs). During monitoring 14 (30%) developed UTIs and 7 (15%) required ureteral reimplant or UV takedown. After surgery there was a significant decrease in the proportion of patients with high-grade hydronephrosis, anteroposterior renal pelvis diameter, and maximum ureteral dilatation.
CONCLUSIONS: Refluxing UV is a safe alternative to cutaneous diversion in POM. Most patients had improvement in upper tract dilatation with an acceptable short-term complication rate and need for reoperation (in comparison to routine later reimplantation). Our experience suggests that monitoring alone after UV is feasible, and that selective subsequent reconstruction is a reasonable strategy.
FIELD: veterinary science, agriculture, biotechnology. SUBSTANCE: invention relates to a method of preparing vaccines and a method of prophylaxis of classic swine plague. Vaccine has an attenuated strain "KS" of classic swine plague virus and dried milk as a stabilizing agent. Vaccine shows the enhanced activity against classic swine plague and its administration at high doses ensures to abolish diseases in unfortunate large swine breeding farms. EFFECT: enhanced effectiveness of vaccine, improved method of prophylaxis. 3 cl
Patients in this group will receive IV acetaminophen and an oral placebo. The IV formulation will be given using the FDA approved OFIRMEV which comes in a single glass bottle at a concentration of 1000mg/100ml (10mg/ml) containing a total of 1 gram of acetaminophen.
We hypothesize, due to the Sjögren's syndrome (SS) disease characteristics, that the primary target hit by the disease process is the secretory acinar cell and that this cell is particularly in women damaged due to insufficient support, normally provided by dehydroepiandrosterone and its intracrine processing. Dehydroepiandrosterone deficiency at the time of adrenopause seems to us as the more likely endocrine trigger than estrogen deficiency caused by menopause as androgens in general are considered to be protective against autoimmunity and estrogens to favor it. Acinar cell is normally responsible for the production of primary saliva. Acinar cell damage can lead to acinar cell apoptosis and loss. Normally this is compensated by division of the acinar cells in situ or, according to recent reports, perhaps rather by division and subsequent migration of one of the daughter cells into the acinar space and transdifferentiation of this intercalated ductal cell progenitor into mature acinar cell. In SS this remodeling seems to be impaired, perhaps for the same reason, which also leads to primary acinar cell damage. According to this hypothesis, the primary changes occur in the salivary glands and more specifically in the acinar cells, whereas immune activation and autoimmunity are secondarily activated against abnormally damaged acinar cells so that individuals with the "right" genetic background also produce SS-A and SS-B antibodies. The cause of the acinar cell damage may not be a direct, damaging stimulus, e.g. virus infection or irradiation damage, but rather lack of a supporting anabolic stimulus and inadequate maintenance of the acinar cell health leading to cytopathic acinar cell changes. In peri-menopausal women (who still produce some estrogens) this abnormal antigen release and processing from acinar cells, which reveals cryptic epitopes, together with autoimmunity enhancing effects of estrogens, may lead to the full picture of SS (Cutolo et al., 2004).

This neuroimmunoendocrine working hypothesis would explain many central disease characteristics, but does not provide a final answer to the mystery of this intriguing syndrome as the reasons for the insufficient production and generation of DHEA remain to be solved. We have done some preliminary studies to analyze this topic by mapping the signals of the extracellular matrix in the adrenal cortex, where the cells proliferate in the outer zone and subsequently migrate in a centripetal direction, during which phenotypic transition occurs from the outer zone (zona glomerulosa) cells producing aldosterone to the intermediate zone (zona fasciculata) cells producing glucocorticosteroids and finally to the inner zone (zona reticularis) cells producing DHEA. However, in this research project we have decided to totally focus on the salivary gland acinar cell-sex steroid interactions.
Enrolled patients with tumors that developed CIPN of degree II or greater who received albumin-bound paclitaxel chemotherapy. The baseline degree of CIPN in patients was evaluated by CTCAE and TNS as well as the EORTC-CIPN20 scale. EGCG was purchased from HEP Biotech Co., Ltd (Ningbo, Zhejiang, China) and freshly dissolved in 75% alcohol by volume. EGCG concentrations were climbed from 1% according to the modified Fibonacci method for 4 dose groups. EGCG administration was initiated when Grade II CIPN occurred first time. EGCG solution is applied to the patient's hands/feet with a soft-bristled brush, approximately 0.05 ml/cm2. 3 times daily, and may be covered with film gloves/cling film for approximately 20-30 minutes after application. Use continuously for at least 1 week. By comparing and analyzing the degree of reduction in CECAE, TNS, and EORTC scale data before and after EGCG treatment in patients with degree II CIPN, the optimal EGCG drug dosing concentration was obtained to validate safety. The EGCG concentration obtained from the phase I trial was also used to prospectively conduct a randomized controlled phase II clinical trial to further validate the efficacy.
1. A hygienic set for a bath or a shower bath or a shower bath comprising: (A) a light weight polymeric meshed personal cleansing hand held sponge; said polymeric mesh sponge being in a form suitable for use as a hand held cleansing implement; (B) a liquid cleanser comprising (1) an effective amount of surfactant selected from the group consisting of anionics, nonionics, cationics, zwitterionics and/or amphoterics and mixtures thereof; and (2) 0.01 to 10% by wt.of a deodorant composition comprising from 45 to 100% by weight of deodorant components, said components having a lipoxidase-inhibiting capacity of at least 50% or a Raoult variance ratio of at least 1.1, said components being classified into six classes consisting of: Class 1: phenolic substances; Class 2: essential oils, extracts, resins and synthetic oils; Class 3: aldehydes and ketones; Class 4: polycyclic compounds; Class 5: esters; Class 6: alcohols, provided that where a component can be classified into more than one class, it is placed in the lower or lowest numbers class: said components being so selected that (a) the deodorant composition contains at lest five components of which at least one must be selected from each of class 1, class 2 and class 4; (b) the deodorant composition contains components from at least 4 of the 6 classes; and  (c) any component present in the deodorant composition at a concentration of less than 0.5% by weight of said composition is eliminated from the requirements of (a) and (b) said deodorant composition having a deodorant value of from 0.50 to 3.5 as measured by Deodorant Value Test. 2. A set according to claim 1 wherein the light weight polymeric meshed personal cleansing hand held polymeric mesh sponge is made of polyethylene diamond mesh and has a diameter of from 3 to 5 inches (7.62 cm to about 12.7 cm). 3. A set according to claim 1, wherein the surfactant system comprises: (a) 1% to 15% by wt. total composition of an acylisethionate; (b) 1 to 15% by wt. of the total composition of an anionic surfactant other than acylisethionate; and (c) 0.5 to 15% by wt. of total composition amphoteric. 4. A method of delivery and deposition of a liquid cleanser comprising a deodorant perfume composition further comprising (a) applying to a substrate selected from the group consisting of skin, a polymeric meshed sponge and combinations thereof. (1) an effective amount of surfactant selected from the group consisting of synthetic surfactants and mixtures thereof; and (2) a deodorant perfume composition as defined in claim 1; and (b) rubbing said polymeric meshed sponge against skin to spread the liquid cleanser.
The Hadassah Hebrew University Medical Centers' Clinical Pharmacy team initiated a hospital-wide program, in collaboration with the institutions' coagulation specialists, including two hematologists and a clinical pharmacologist, for monitoring and promoting safe and effective prescription of direct oral anticoagulants (DOAC) during hospitalization. Electronic medical records throughout the hospital are screened for DOAC orders. All DOAC orders are assessed by a clinical pharmacist for potentially-inappropriate prescribing. When potentially-inappropriate prescribing or a drug-related problem is identified, the clinical pharmacist provided consultation on management options. In specific cases, additional guidance is provided by coagulation specialists. Consultations are recorded in the electronic medical record. Performance measures are collected and summarized.
### Renal Toxicity

Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. 

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics, ACE inhibitors or the ARBs, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state. 

No information is available from controlled clinical studies regarding the use of celecoxib in patients with advanced renal disease. The renal effects of celecoxib capsules may hasten the progression of renal dysfunction in patients with preexisting renal disease. 

Correct volume status in dehydrated or hypovolemic patients prior to initiating celecoxib capsules. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of celecoxib [see Drug Interactions (7)]. Avoid the use of celecoxib in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function. If celecoxib is used in patients with advanced renal disease, monitor patients for signs of worsening renal function.

### Hyperkalemia

Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic- hypoadosteronism state.
PURPOSE: A novel bispecific monoclonal antibody and a composition for cancer treatment including the same with improved anticancer activities are provided to express improved antibody dependent cellular cytotoxicity. CONSTITUTION: A novel bispecific monoclonal antibody comprises an antibody which combines with the cancer cell surface antigen and a domain which combines with immunocyte surface antigen. A domain which binds with the immunocyte surface antigen is connected with linker at the C-terminal of Fc domain in antibody which binds with the cancer cell surface antigen. The antibody bonded with the cancer cell surface antigen is in IgG form. The domain bonded with the immunocyte surface antigen is in scFv(Single-chain variable fragment) form. The linker is peptide. The linker peptide has the sequence number 4(SEQ ID NO:4).
DHP (fixed dosage combination tablets containing 40 mg dihydroartemisinin and 320 mg piperaquine) was administered to the group for 3 days, with primaquine being administered for 14 days to patients with Plasmodium vivax and 1 day initially to those with Plasmodium falciparum without difficulties. Body weight is taken into consideration while setting therapy parameters (age 15 years, \>40-60 kg: 3 tablets; \>60-80 kg: 4 tablets; 80 kg: 5 tablets).
The invention provides a new paclitaxel with high bioavailability and an oral pharmaceutical preparation of ramification of the paclitaxel; the pharmaceutical preparation forms supersaturated medicament state solution in the human body to further enhance the bioavailability of the paclitaxel and the oral preparation of the ramification thereof. The preparation contains the paclitaxel with high content and the ramification thereof and shows sufficient physics and chemistry stability. The preparation contains less poly-ethoxy castor oil. The preparation is the application based on including the paclitaxel and the ramification thereof, solvent, surface active agent and nemaline polymer, and is self-emulsification. Latex or microemulsion rapidly and effectively absorbs the paclitaxel and the ramification thereof and ensures the bioavailability of the paclitaxel and the ramification thereof to be enhanced. Under the designated situation, the preparation also contains a diglyceride or the mixture of the diglyceride and monoglyceride; the content of the paclitaxel in the preparation can reach about 100mg/g, so as to reduce the intake quantity of the complex for the patients.
FIELD: medicine. SUBSTANCE: method involves isolation of fraction showing maximal NADH-oxidase activity due to increased purification degree of the end product. Source raw: nonconditioned, preliminary used low-mineralized slime sulfide silt which were decalcined and desulfurized with 2M hydrochloric acid solution, washed with water, extracted with 0.5M sodium hydroxide solution, filtered, precipitated with 50% sulfuric acid solution. Precipitate is washed with water, ethanol, dissolved in 0.02M sodium hydroxide solution followed by repeated precipitation. Precipitate washed with water is dissolved in 0.02M sodium hydroxide solution is passed through cationite in H + -form and dried. EFFECT: improved method of preparation preparing.
The invention discloses a processing method for switching medicine units of an intelligent clinic system, which comprises the following steps: firstly, unit extraction is carried out on different forms of the medicine; step two: according to the size information of the medicine units, unit marking is carried out on the medicine units; step three: storing the drug information according to the relationship between the marking value and the corresponding drug unit and the conversion ratio of each level; step four: when the medicine unit is used for the first time, only the mark information of the unit is recorded, and the specific value of the unit does not need to be recorded; step five: when the medicine is used again and reused, the corresponding medicine unit information can be accurately acquired through the stored mark value. The invention comprises the following steps: 1. the method is suitable for scenes that medicine units need to be flexibly switched. 2. The conversion ratio can be quickly determined after the unit switching. 3. And automatically calculating the total quantity of the switched medicines after unit switching. 4. The method is suitable for the scene that the data needs to be reused after the medicine data is used.
Bronchoscopic lung volume reduction (BLVR) is an established treatment modality for the management of advanced chronic obstructive pulmonary disease complicated by severe emphysema and hyperinflation refractory to other therapies. BLVR aims to reduce hyperinflation and residual volume, thereby improving pulmonary function, symptom control, and quality of life. Multiple distinct devices and technologies, including endobronchial coils, thermal vapor ablation, bio-lung volume reduction, and airway bypass stenting, have been developed to achieve lung volume reduction with varying degrees of accessibility and evidence. The most promising BLVR treatment modality to date has been the placement of one-way endobronchial valves (EBVs), with more than 25,000 cases performed worldwide. Identifying symptomatic patients who would benefit from BLVR is challenging and can be time and resource intensive, and candidacy may be limited by physiologic parameters. Additional new technologies may be able to improve the identification and evaluation of candidates as well as increase the portion of evaluated patients who ultimately qualify for BLVR. In this review, we aim to provide historical context to BLVR, summarize the available evidence regarding its use, discuss potential complications, and provide readers with a clear guide to patient selection and referral for BLVR, with a focus on EBV placement. In addition, we will highlight potential future directions for the field.
Patients belonging to the intervention group presented abfraction lesions in upper and/or lower premolars. These abfraction lesions consist of a loss of dental hard tissue at the cervical level of more than 1 mm, and are associated with type 1 gingival recession of the Cairo classification.
FIELD: process engineering.SUBSTANCE: invention relates cosmetic industry, particularly, to processing of mica including grinding, holding in chemically active matter, filtration, flushing, drying and baking. Proposed method differs from known process in that baking is performed before processing by chemically active matter at temperature not exceed that of fold fusion followed by cooling at room temperature. Note here that baking accompanied with cooling is performed 7 times. Said chemically active matter represents a decoction prepared of rye, wheat and herbs Punarnava Himalaya and Emblica Officinalis after filtration and flushing. Obtained precipitate is held in cow's milk. Then, said precipitate is filtered and held in heated melted butter wherefrom water, lactalbumin and lactose are removed. Thereafter, obtained mica filtrate is additionally ground with onion sap and dried, at least 7 times. Then, ground rye, wheat and sesame oil are added to obtained mica at the following ratio, i.e. mica-rye - 1:1, mica-wheat 1:1, and mica-sesame oil 1:5. Obtained mix is heated on water bath for 3-5 h with subsequent mica separation by filtration. Note also that holding of mica in decoction is performed for 3-5 h at room temperature, in milk for 2-3 h and in heated melted butter for 3-5 h.EFFECT: expanded applications of mica in production of cosmetics.2 cl, 4 tbl
There is no doubt about the importance of a physical activity at a later age, yet it is often missing in the lives of seniors and the current epidemiological situation deepens this deficit even further. It is known that insufficient physical activity has a major effect on the decline of functional fitness components, premature development of sarcopenia or frailty syndrome, threatening self-sufficiency, health and consequently quality of life. This is associated with an increased burden on the health care system and related social services, with implications for public budgets. The aim of this project is to eliminate the onset or premature manifestation of negative aspects of aging by prevention. The content is to research a unique intervention inspired by the principles of developmental kinesiology with a presumed positive effect on the health status and the development of a comprehensive exercise and educational program for older adults. The main planned result of the project is a methodological manual and a web application containing education and exercise program for both older adults as well healthcare professionals.

The project responds to the priorities of the Applied Health Research Program for the years 2020-2026 and its focus contributes to a long-term solution of the population aging issue. With regard to demographic change, health and social care systems will be unsustainable without the adoption of preventive measures by seniors themselves. Exercise-educational intervention can lead to lasting changes and can help seniors to actively and responsibly participate in the course of their own aging. Main objective: to reduce negative health related aspects of aging, resp. their premature manifestation, by a preventive exercise-educational program. Sub-objectives: - to develop a specifically targeted exercise-educational program; - to demonstrate effectiveness of the program on health and social related indicators; - to assess acceptability, sustainability and other personal contexts - to create a methodological manual and a web platform for home-dwelling as well as institutionalized older adults containing complex information for independent exercise (how, as well as why).
The present invention involves a pharmaceutical formulation comprising a liposome having a therapeutically effective concentration of an aromatic polyene macrolide antibiotic. The aromatic polyene macrolide antibiotic usable in the practice of the present invention is selected from the group consisting of candicidin, hamycin, aurefungin, ascosin, ayfattin, azacolutin, DJ400-B, trichomycin, levorin, heptamycin, candimycin or perimycin. The most preferred aromatic polyene macrolide antibiotic is candicidin. An important aspect of the present invention is a method for treating disseminated fungal infection in an animal comprising administering to an animal such as a human a pharmaceutical formulation comprising a liposome having a therapeutically effective amount of aromatic polyene macrolide antibiotic as described above. The preferred method of such administering is parenteral and the therapeutically effective amount is between about 1 mg/kg body weight and about 20 mg/kg body weight, more preferably between about 2.5 mg/kg body weight and about 6 mg/kg body weight. The parenteral administration is intravenous, intraarterial, subcutaneous, intramuscular, intralymphatic, intraperitoneal or intrapleural. The microorganisms which may be treated by the methods of the present invention comprise $i(C. albicans, C. tropicalis, C. neoformans), aspergillus, cryptococcus, phycomycetes, fusarium, or trichosporin.
Women in the experimental group will receive an 8-week online intervention program based on interpersonal relationships. An internet-based intervention application will be developed for this intervention. All interventions will be implemented from this intervention.
The invention relates to a macromolecular active aloe juice preparation method and belongs to the technical field of plant processing. The method includes following steps: (1) crushing and sterilizing aloe raw material to obtain aloe raw pulp; (2) purifying and centrifuging the aloe raw pulp to obtain aloe raw liquid; (3) performing ionic exchange adsorption to remove anthraquinone; and (4) finally performing sterilization to obtain macromolecular active aloe juice. The method is easy to operate and control and is good in anthraquinone removal effect. The macromolecular active aloe juice is less than 0.1 mg/kg in the content of aloin. The method allows employed resin to be recyclable, thereby reducing environmental pollution and production cost. Meanwhile, because the ionic exchange resin has specificity and is short in contact time, polysaccharides and functional components in the macromolecular active aloe juice are not loss. The method is excellent in social benefit and economical benefit.